Revealing tumor immunity after hematopoietic stem cell transplantation

Catherine J Wu; Jerome Ritz

doi:10.1158/1078-0432.CCR-09-0873

Revealing tumor immunity after hematopoietic stem cell transplantation

Clin Cancer Res. 2009 Jul 15;15(14):4515-7. doi: 10.1158/1078-0432.CCR-09-0873. Epub 2009 Jul 7.

Authors

Catherine J Wu¹, Jerome Ritz

Affiliation

¹ Cancer Vaccine Center, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.

PMID: 19584145
DOI: 10.1158/1078-0432.CCR-09-0873

Abstract

Allogeneic hematopoietic stem cell transplantation is currently the most effective method for inducing tumor immunity. However, the diversity of target antigens recognized by donor T cells has not been established. New studies show that tumor-reactive T cells are directed against diverse tumor-specific targets as well as minor histocompatibility antigens.

Publication types

Comment

MeSH terms

Animals
Cytotoxicity, Immunologic / immunology
Graft vs Host Disease / immunology
Hematopoietic Stem Cell Transplantation / methods*
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / blood
Leukemia, Lymphocytic, Chronic, B-Cell / immunology*
Leukemia, Lymphocytic, Chronic, B-Cell / surgery*
Leukocytes, Mononuclear / cytology
Leukocytes, Mononuclear / immunology
Models, Immunological
T-Lymphocytes / cytology
T-Lymphocytes / immunology*
Transplantation, Homologous
Treatment Outcome